Guidelines for Eczema Management and Prevention of Post‑Inflammatory Scarring
1. Topical Corticosteroid Therapy
- For active eczema, apply moderate‑to‑potent topical corticosteroids (e.g., mometasone furoate or clobetasol propionate 0.05 %) twice daily to all affected areas until clinical clearance, then switch to twice‑weekly proactive maintenance on previously involved skin to reduce relapses and scarring. 1
- The potency and duration of topical corticosteroid treatment must be matched to disease severity and location, using the lowest effective potency. 1
- Moderate‑to‑potent corticosteroids should be applied no more than twice daily to active lesions, typically achieving significant improvement within 2–4 weeks. 1
- Very potent corticosteroids should be avoided on the face, neck, intertriginous areas, and genital skin because of the high risk of atrophy and telangiectasia. 1
2. Emollient Therapy (Barrier Restoration)
- Emollient therapy should be continued daily regardless of disease activity, as it is the cornerstone of eczema management. 1
- Apply fragrance‑free emollients liberally within 10–15 minutes after bathing to damp skin to form a lipid film that reduces transepidermal water loss and restores barrier function. 1
- Ongoing aggressive emollient use during clear periods provides documented steroid‑sparing benefits and prolongs recurrence‑free intervals. 1
3. Proactive Maintenance to Prevent Relapse and Scarring
- After clearance, proactive maintenance therapy consists of applying the same corticosteroid twice weekly (e.g., weekend therapy) for up to 16 weeks to prevent relapse and subsequent post‑inflammatory hyperpigmentation or scarring. 1
- Proactive maintenance has been validated in children with moderate‑to‑severe atopic dermatitis using low‑to‑medium potency agents. 1
4. Calcineurin Inhibitor Alternatives
- Topical calcineurin inhibitors (tacrolimus 0.03–0.1 % ointment or pimecrolimus 1 % cream) are steroid‑sparing options for patients aged ≥ 2 years, especially for facial eczema and as part of proactive maintenance. 1
- Calcineurin inhibitors do not cause skin atrophy, making them preferred for long‑term use on sensitive areas. 1
5. Wet‑Wrap Therapy (Second‑Line Short‑Term Treatment)
- Wet‑wrap therapy with topical corticosteroids is an effective short‑term second‑line treatment for moderate‑to‑very severe eczema that has failed conventional topical therapy. 1
- Recommended wet‑wrap duration is 3–7 days, with possible extension to 14 days in severe cases. 1
- Wet‑wraps enhance trans‑epidermal penetration of corticosteroids and act as a physical barrier against scratching. 1